MECP2 and breast carcinoma: showed that ROR sponged miR-194-3p and upregulated the expression of a miR-194-3p target, the methyl-CpG-binding protein 2 (MECP2) gene, to decrease the sensitivity of breast cancer cells to rapamycin (82).